Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
Тип публикации: Journal Article
Дата публикации: 2019-06-21
SCImago Q1
Tоп 10% SCImago
WOS Q1
БС3
SJR: 1.775
CiteScore: 8.3
Impact factor: 5.2
ISSN: 2578532X
PubMed ID:
35582577
Краткое описание
Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Топ-30
Журналы
|
1
|
|
|
Journal of Nanobiotechnology
1 публикация, 12.5%
|
|
|
Frontiers in Microbiology
1 публикация, 12.5%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
1 публикация, 12.5%
|
|
|
Archives of Pharmacal Research
1 публикация, 12.5%
|
|
|
Phytomedicine
1 публикация, 12.5%
|
|
|
International Journal of Biological Macromolecules
1 публикация, 12.5%
|
|
|
Biomedicine and Pharmacotherapy
1 публикация, 12.5%
|
|
|
Russian Chemical Reviews
1 публикация, 12.5%
|
|
|
1
|
Издатели
|
1
2
3
4
|
|
|
Elsevier
4 публикации, 50%
|
|
|
Springer Nature
2 публикации, 25%
|
|
|
Frontiers Media S.A.
1 публикация, 12.5%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 12.5%
|
|
|
1
2
3
4
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
8
Всего цитирований:
8
Цитирований c 2025:
2
(25%)
Цитировать
ГОСТ |
RIS |
BibTex
Цитировать
ГОСТ
Скопировать
Mathieu C. et al. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins // Cancer Drug Resistance. 2019. Vol. 2. No. 3.
ГОСТ со всеми авторами (до 50)
Скопировать
Mathieu C., Messaoudi S., Fattal E., Vergnaud-Gauduchon J. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins // Cancer Drug Resistance. 2019. Vol. 2. No. 3.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.20517/cdr.2019.26
UR - https://doi.org/10.20517/cdr.2019.26
TI - Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
T2 - Cancer Drug Resistance
AU - Mathieu, Clélia
AU - Messaoudi, Samir
AU - Fattal, Elias
AU - Vergnaud-Gauduchon, Juliette
PY - 2019
DA - 2019/06/21
PB - OAE Publishing Inc.
IS - 3
VL - 2
PMID - 35582577
SN - 2578-532X
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2019_Mathieu,
author = {Clélia Mathieu and Samir Messaoudi and Elias Fattal and Juliette Vergnaud-Gauduchon},
title = {Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins},
journal = {Cancer Drug Resistance},
year = {2019},
volume = {2},
publisher = {OAE Publishing Inc.},
month = {jun},
url = {https://doi.org/10.20517/cdr.2019.26},
number = {3},
doi = {10.20517/cdr.2019.26}
}
Ошибка в публикации?